Skip to main
CODX

Co-Diagnostics (CODX) Stock Forecast & Price Target

Co-Diagnostics (CODX) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Co-Diagnostics Inc. is positioned favorably within the expanding market for respiratory infectious disease diagnostics, particularly due to significant investments in the Kingdom of Saudi Arabia and a strategic partnership through its Joint Venture, CoMira Diagnostics, which will enhance its capabilities in the region. The development of a proprietary sample preparation instrument aimed at reducing the cost of processing samples for point-of-care PCR testing showcases the company’s commitment to improving accessibility to essential health technologies globally. Additionally, ongoing advancements in their Co-Dx PCR platform, including the pursuit of regulatory clearances for a refined COVID-19 test, indicate a robust trajectory in expanding their product offerings and market presence.

Bears say

Co-Diagnostics Inc faces significant risks that could adversely impact its financial performance, including potential failures in clinical evaluations, regulatory clearances, and competition, which jeopardize its market penetration and commercial success. The company's recent financial results indicate a troubling trend, with revenue at only $145,000 for the third quarter of 2025, while incurring a net loss of $5.9 million, translating to a loss of $0.16 per share. Additionally, concerns regarding future fundraising imply increasing dilution and less favorable terms, further complicating the company's financial stability.

Co-Diagnostics (CODX) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Co-Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Co-Diagnostics (CODX) Forecast

Analysts have given Co-Diagnostics (CODX) a Buy based on their latest research and market trends.

According to 3 analysts, Co-Diagnostics (CODX) has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Co-Diagnostics (CODX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.